ArticleFrontiers in aging neuroscience2026
Prediction of cognitive impairment in Parkinson's disease using TabPFN: an integrative analysis of clinical data, longitudinal trajectories, and lipidomics.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment is a common and disabling non-motor manifestation of Parkinson's disease (PD). Early identification of patients at high risk remains challenging, and the metabolic mechanisms underlying cognitive decline are not fully understood. Methods: We conducted a retrospective cohort study including PD patients who were cognitively normal at baseline. A machine learning model based on a Tabular Prior-data Fitted Network (TabPFN) was developed using routinely collected clinical and laboratory data to predict future cognitive impairment. Model performance was evaluated using stratified group cross-validation and external validation in the Parkinson's Progression Markers Initiative (PPMI) cohort. Model interpretability was assessed using SHapley Additive exPlanations (SHAP). Longitudinal analyses and untargeted lipidomics were performed to explore temporal and molecular alterations associated with cognitive decline. Results: Among 91 patients in the internal cohort, 45 developed cognitive impairment during follow-up. The TabPFN model achieved an AUC of 0.822 (95% CI 0.709-0.889) in internal validation and 0.742 (95% CI 0.695-0.783) in external validation. In internal benchmark comparisons, TabPFN showed numerically higher discrimination than logistic regression (AUC = 0.728) and random forest (AUC = 0.787). MoCA and age were the most influential predictors, while triglycerides (TG) also contributed to model predictions. In the longitudinal analysis, TG trajectories differed between converters and stable participants after adjustment for relevant covariates (group-by-time interaction: β = -0.146, 95% CI - 0.248 to -0.044; Conclusion: A TabPFN-based model using routinely available clinical and biochemical variables showed promising discrimination for future cognitive impairment in PD. TG contributed to prediction, and longitudinal analyses identified different TG trajectories between converters and stable participants. The cross-sectional lipidomics findings provide complementary, hypothesis-generating information about molecular lipid heterogeneity but do not establish the mechanism underlying the longitudinal TG pattern. Prospective multicenter validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.